메뉴 건너뛰기




Volumn , Issue , 2013, Pages 73-84

Blood-based tumor markers for prostate cancer

Author keywords

[No Author keywords available]

Indexed keywords


EID: 84921453155     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-62703-188-2_7     Document Type: Chapter
Times cited : (1)

References (101)
  • 1
    • 63249118690 scopus 로고    scopus 로고
    • Screening and prostate-cancer mortality in a randomized European study
    • Schroder FH, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009;360(13):1320-8.
    • (2009) N Engl J Med , vol.360 , Issue.13 , pp. 1320-1328
    • Schroder, F.H.1
  • 2
    • 12744251833 scopus 로고    scopus 로고
    • Beyond prostate-specific antigen: new serologic biomarkers for improved diagnosis and management of prostate cancer
    • Shariat SF, et al. Beyond prostate-specific antigen: new serologic biomarkers for improved diagnosis and management of prostate cancer. Rev Urol. 2004;6(2): 58-72.
    • (2004) Rev Urol , vol.6 , Issue.2 , pp. 58-72
    • Shariat, S.F.1
  • 3
    • 44149085674 scopus 로고    scopus 로고
    • Perspectives on prostate cancer biomarkers
    • Shariat SF, Karakiewicz PI. Perspectives on prostate cancer biomarkers. Eur Urol. 2008;54(1):8-10.
    • (2008) Eur Urol , vol.54 , Issue.1 , pp. 8-10
    • Shariat, S.F.1    Karakiewicz, P.I.2
  • 4
    • 79957461212 scopus 로고    scopus 로고
    • Tumor markers in prostate cancer I: blood-based markers
    • Shariat SF, et al. Tumor markers in prostate cancer I: blood-based markers. Acta Oncol. 2011;50 (Suppl 1): 61-75.
    • (2011) Acta Oncol , vol.50 , pp. 61-75
    • Shariat, S.F.1
  • 5
    • 0035100888 scopus 로고    scopus 로고
    • Biomarkers and surrogate endpoints: preferred definitions and conceptual framework
    • Atkinson AJ, et al. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001;69(3):89-95.
    • (2001) Clin Pharmacol Ther , vol.69 , Issue.3 , pp. 89-95
    • Atkinson, A.J.1
  • 6
    • 35748947727 scopus 로고    scopus 로고
    • Challenges of cancer biomarker profiling
    • Bensalah K, Montorsi F, Shariat SF. Challenges of cancer biomarker profiling. Eur Urol. 2007;52(6): 1601-9.
    • (2007) Eur Urol , vol.52 , Issue.6 , pp. 1601-1609
    • Bensalah, K.1    Montorsi, F.2    Shariat, S.F.3
  • 7
    • 43549084349 scopus 로고    scopus 로고
    • New circulating biomarkers for prostate cancer
    • Bensalah K, et al. New circulating biomarkers for prostate cancer. Prostate Cancer Prostatic Dis. 2008;11(2):112-20.
    • (2008) Prostate Cancer Prostatic Dis , vol.11 , Issue.2 , pp. 112-120
    • Bensalah, K.1
  • 8
    • 0642344849 scopus 로고    scopus 로고
    • New cancer biomarkers deriving from NCI early detection research
    • discussion 264-6.
    • Verma M, Srivastava S. New cancer biomarkers deriving from NCI early detection research. Recent Results Cancer Res. 2003;163:72-84. discussion 264-6.
    • (2003) Recent Results Cancer Res , vol.163 , pp. 72-84
    • Verma, M.1    Srivastava, S.2
  • 9
    • 0037392777 scopus 로고    scopus 로고
    • Development of common data elements: the experience of and recommendations from the early detection research network
    • Winget MD, et al. Development of common data elements: the experience of and recommendations from the early detection research network. Int J Med Inform. 2003;70(1):41-8.
    • (2003) Int J Med Inform , vol.70 , Issue.1 , pp. 41-48
    • Winget, M.D.1
  • 10
    • 56649117652 scopus 로고    scopus 로고
    • An updated catalog of prostate cancer predictive tools
    • Shariat SF, et al. An updated catalog of prostate cancer predictive tools. Cancer. 2008;113(11):3075-99.
    • (2008) Cancer , vol.113 , Issue.11 , pp. 3075-3099
    • Shariat, S.F.1
  • 11
    • 39449122483 scopus 로고    scopus 로고
    • New blood-based biomarkers for the diagnosis, staging and prognosis of prostate cancer
    • Shariat SF, et al. New blood-based biomarkers for the diagnosis, staging and prognosis of prostate cancer. BJU Int. 2008;101(6):675-83.
    • (2008) BJU Int , vol.101 , Issue.6 , pp. 675-683
    • Shariat, S.F.1
  • 12
    • 34548452553 scopus 로고    scopus 로고
    • Plasminogen activation inhibitor-1 improves the predictive accuracy of prostate cancer nomograms
    • discussion 1236-7.
    • Shariat SF, et al. Plasminogen activation inhibitor-1 improves the predictive accuracy of prostate cancer nomograms. J Urol. 2007;178(4 Pt 1):1229-36. discussion 1236-7.
    • (2007) J Urol , vol.178 , Issue.4 , pp. 1229-1236
    • Shariat, S.F.1
  • 13
    • 0037613523 scopus 로고    scopus 로고
    • Judging new markers by their ability to improve predictive accuracy
    • Kattan MW. Judging new markers by their ability to improve predictive accuracy. J Natl Cancer Inst. 2003;95(9):634-5.
    • (2003) J Natl Cancer Inst , vol.95 , Issue.9 , pp. 634-635
    • Kattan, M.W.1
  • 14
    • 34447646946 scopus 로고    scopus 로고
    • Method for evaluating prediction models that apply the results of randomized trials to individual patients
    • Vickers AJ, Kattan MW, Daniel S. Method for evaluating prediction models that apply the results of randomized trials to individual patients. Trials. 2007; 8:14.
    • (2007) Trials , vol.8 , pp. 14
    • Vickers, A.J.1    Kattan, M.W.2    Daniel, S.3
  • 15
    • 0142008439 scopus 로고    scopus 로고
    • The addition of interleukin-6 soluble receptor and transforming growth factor beta1 improves a preoperative nomogram for predicting biochemical progression in patients with clinically localized prostate cancer
    • Kattan MW, et al. The addition of interleukin-6 soluble receptor and transforming growth factor beta1 improves a preoperative nomogram for predicting biochemical progression in patients with clinically localized prostate cancer. J Clin Oncol. 2003;21(19): 3573-9.
    • (2003) J Clin Oncol , vol.21 , Issue.19 , pp. 3573-3579
    • Kattan, M.W.1
  • 16
    • 50849143820 scopus 로고    scopus 로고
    • Improved prediction of disease relapse after radical prostatectomy through a panel of preoperative blood-based biomarkers
    • Shariat SF, et al. Improved prediction of disease relapse after radical prostatectomy through a panel of preoperative blood-based biomarkers. Clin Cancer Res. 2008;14(12):3785-91.
    • (2008) Clin Cancer Res , vol.14 , Issue.12 , pp. 3785-3791
    • Shariat, S.F.1
  • 17
    • 48249152185 scopus 로고    scopus 로고
    • A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: data from the European Randomized Study of prostate cancer screening in Goteborg, Sweden
    • Vickers AJ, et al. A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: data from the European Randomized Study of prostate cancer screening in Goteborg, Sweden. BMC Med. 2008;6:19.
    • (2008) BMC Med , vol.6 , pp. 19
    • Vickers, A.J.1
  • 18
    • 42149185603 scopus 로고    scopus 로고
    • Systematic review of statistical methods used in molecular marker studies in cancer
    • Vickers AJ, et al. Systematic review of statistical methods used in molecular marker studies in cancer. Cancer. 2008;112(8):1862-8.
    • (2008) Cancer , vol.112 , Issue.8 , pp. 1862-1868
    • Vickers, A.J.1
  • 19
    • 21444447966 scopus 로고    scopus 로고
    • Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower
    • Thompson IM, et al. Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower. JAMA. 2005;294(1): 66-70.
    • (2005) JAMA , vol.294 , Issue.1 , pp. 66-70
    • Thompson, I.M.1
  • 20
    • 38049047956 scopus 로고    scopus 로고
    • Multiple biomarkers improve prediction of bladder cancer recurrence and mortality in patients undergoing cystectomy
    • Shariat SF, et al. Multiple biomarkers improve prediction of bladder cancer recurrence and mortality in patients undergoing cystectomy. Cancer. 2008;112(2): 315-25.
    • (2008) Cancer , vol.112 , Issue.2 , pp. 315-325
    • Shariat, S.F.1
  • 21
    • 33750905259 scopus 로고    scopus 로고
    • Decision curve analysis: a novel method for evaluating prediction models
    • Vickers AJ, Elkin EB. Decision curve analysis: a novel method for evaluating prediction models. Med Decis Making. 2006;26(6):565-74.
    • (2006) Med Decis Making , vol.26 , Issue.6 , pp. 565-574
    • Vickers, A.J.1    Elkin, E.B.2
  • 22
    • 58149269742 scopus 로고    scopus 로고
    • Extensions to decision curve analysis, a novel method for evaluating diagnostic tests, prediction models and molecular markers
    • Vickers AJ, et al. Extensions to decision curve analysis, a novel method for evaluating diagnostic tests, prediction models and molecular markers. BMC Med Inform Decis Mak. 2008;8:53.
    • (2008) BMC Med Inform Decis Mak , vol.8 , pp. 53
    • Vickers, A.J.1
  • 23
    • 55049116162 scopus 로고    scopus 로고
    • Decision analysis for the evaluation of diagnostic tests, prediction models and molecular markers
    • Vickers AJ. Decision analysis for the evaluation of diagnostic tests, prediction models and molecular markers. Am Stat. 2008;62(4):314-20.
    • (2008) Am Stat , vol.62 , Issue.4 , pp. 314-320
    • Vickers, A.J.1
  • 24
    • 33747171381 scopus 로고    scopus 로고
    • Primer: using decision analysis to improve clinical decision making in urology
    • Elkin EB, Vickers AJ, Kattan MW. Primer: using decision analysis to improve clinical decision making in urology. Nat Clin Pract Urol. 2006;3(8): 439-48.
    • (2006) Nat Clin Pract Urol , vol.3 , Issue.8 , pp. 439-448
    • Elkin, E.B.1    Vickers, A.J.2    Kattan, M.W.3
  • 25
    • 41149166182 scopus 로고    scopus 로고
    • Prostate-specific antigen and prostate cancer: prediction, detection and monitoring
    • Lilja H, Ulmert D, Vickers AJ. Prostate-specific antigen and prostate cancer: prediction, detection and monitoring. Nat Rev Cancer. 2008;8(4):268-78.
    • (2008) Nat Rev Cancer , vol.8 , Issue.4 , pp. 268-278
    • Lilja, H.1    Ulmert, D.2    Vickers, A.J.3
  • 26
    • 38749107817 scopus 로고    scopus 로고
    • Early detection of prostate cancer in 2007 Part 1: PSA and PSA kinetics
    • Schroder FH, et al. Early detection of prostate cancer in 2007. Part 1: PSA and PSA kinetics. Eur Urol. 2008;53(3):468-77.
    • (2008) Eur Urol , vol.53 , Issue.3 , pp. 468-477
    • Schroder, F.H.1
  • 27
    • 34547903643 scopus 로고    scopus 로고
    • Blood biomarkers for prostate cancer detection and prognosis
    • Shariat SF, Karam JA, Roehrborn CG. Blood biomarkers for prostate cancer detection and prognosis. Future Oncol. 2007;3(4):449-61.
    • (2007) Future Oncol , vol.3 , Issue.4 , pp. 449-461
    • Shariat, S.F.1    Karam, J.A.2    Roehrborn, C.G.3
  • 28
    • 41749085784 scopus 로고    scopus 로고
    • Inventory of prostate cancer predictive tools
    • Shariat SF, et al. Inventory of prostate cancer predictive tools. Curr Opin Urol. 2008;18(3):279-96.
    • (2008) Curr Opin Urol , vol.18 , Issue.3 , pp. 279-296
    • Shariat, S.F.1
  • 29
    • 0027889117 scopus 로고
    • Significance of different molecular forms of serum PSA The free, noncomplexed form of PSA versus that complexed to alpha 1-antichymotrypsin (Review)
    • Lilja H. Significance of different molecular forms of serum PSA. The free, noncomplexed form of PSA versus that complexed to alpha 1-antichymotrypsin (Review). Urol Clin North Am. 1993;20(4):681-6.
    • (1993) Urol Clin North Am , vol.20 , Issue.4 , pp. 681-686
    • Lilja, H.1
  • 30
    • 32044437615 scopus 로고    scopus 로고
    • Pre-operative percent free PSA predicts clinical outcomes in patients treated with radical prostatectomy with total PSA levels below 10 ng/ ml
    • Shariat SF, et al. Pre-operative percent free PSA predicts clinical outcomes in patients treated with radical prostatectomy with total PSA levels below 10 ng/ ml. Eur Urol. 2006;49(2):293-302.
    • (2006) Eur Urol , vol.49 , Issue.2 , pp. 293-302
    • Shariat, S.F.1
  • 31
    • 0033916382 scopus 로고    scopus 로고
    • Comparison of percent free PSA, PSA density, and age-specific PSA cutoffs for prostate cancer detection and staging
    • Catalona WJ, et al. Comparison of percent free PSA, PSA density, and age-specific PSA cutoffs for prostate cancer detection and staging. Urology. 2000;56(2): 255-60.
    • (2000) Urology , vol.56 , Issue.2 , pp. 255-260
    • Catalona, W.J.1
  • 32
    • 0036093686 scopus 로고    scopus 로고
    • Free prostate-specific antigen in serum is becoming more complex
    • Mikolajczyk SD, et al. Free prostate-specific antigen in serum is becoming more complex. Urology. 2002;59(6):797-802.
    • (2002) Urology , vol.59 , Issue.6 , pp. 797-802
    • Mikolajczyk, S.D.1
  • 33
    • 0032550630 scopus 로고    scopus 로고
    • Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial
    • Catalona WJ, et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA. 1998;279(19):1542-7.
    • (1998) JAMA , vol.279 , Issue.19 , pp. 1542-1547
    • Catalona, W.J.1
  • 34
    • 0031986360 scopus 로고    scopus 로고
    • Interpretation of free prostate specific antigen clinical research studies for the detection of prostate cancer
    • Woodrum DL, et al. Interpretation of free prostate specific antigen clinical research studies for the detection of prostate cancer. J Urol. 1998;159(1):5-12.
    • (1998) J Urol , vol.159 , Issue.1 , pp. 5-12
    • Woodrum, D.L.1
  • 35
    • 4143121190 scopus 로고    scopus 로고
    • Effects of systematic 12-core biopsy on the performance of percent free prostate specific antigen for prostate cancer detection
    • Canto EI, et al. Effects of systematic 12-core biopsy on the performance of percent free prostate specific antigen for prostate cancer detection. J Urol. 2004;172(3):900-4.
    • (2004) J Urol , vol.172 , Issue.3 , pp. 900-904
    • Canto, E.I.1
  • 36
    • 33646009994 scopus 로고    scopus 로고
    • A meta-analysis of the performance characteristics of the free prostate-specific antigen test
    • Lee R, et al. A meta-analysis of the performance characteristics of the free prostate-specific antigen test. Urology. 2006;67(4):762-8.
    • (2006) Urology , vol.67 , Issue.4 , pp. 762-768
    • Lee, R.1
  • 37
    • 0030913316 scopus 로고    scopus 로고
    • Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination Enhancement of specificity with free PSA measurements
    • Catalona WJ, Smith DS, Ornstein DK. Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements. JAMA. 1997;277(18):1452-5.
    • (1997) JAMA , vol.277 , Issue.18 , pp. 1452-1455
    • Catalona, W.J.1    Smith, D.S.2    Ornstein, D.K.3
  • 38
    • 20444409181 scopus 로고    scopus 로고
    • Prostate cancer detection in men with a 'normal' total prostate-specific antigen (PSA) level using percentage free PSA: a prospective screening study
    • Rowe EW, et al. Prostate cancer detection in men with a 'normal' total prostate-specific antigen (PSA) level using percentage free PSA: a prospective screening study. BJU Int. 2005;95(9):1249-52.
    • (2005) BJU Int , vol.95 , Issue.9 , pp. 1249-1252
    • Rowe, E.W.1
  • 39
    • 34248163980 scopus 로고    scopus 로고
    • Prevalence and clinical significance of prostate cancer among 12,682 men with normal digital rectal examination, low PSA levels (< or =4 ng/ ml) and percent free PSA cutoff values of 15 and 20%
    • Pepe P, et al. Prevalence and clinical significance of prostate cancer among 12,682 men with normal digital rectal examination, low PSA levels (< or =4 ng/ ml) and percent free PSA cutoff values of 15 and 20%. Urol Int. 2007;78(4):308-12.
    • (2007) Urol Int , vol.78 , Issue.4 , pp. 308-312
    • Pepe, P.1
  • 40
    • 0036162855 scopus 로고    scopus 로고
    • Percent free prostate specific antigen is not an independent predictor of organ confinement or prostate specific antigen recurrence in unscreened patients with localized prostate cancer treated with radical prostatectomy
    • Graefen M, et al. Percent free prostate specific antigen is not an independent predictor of organ confinement or prostate specific antigen recurrence in unscreened patients with localized prostate cancer treated with radical prostatectomy. J Urol. 2002; 167(3):1306-9.
    • (2002) J Urol , vol.167 , Issue.3 , pp. 1306-1309
    • Graefen, M.1
  • 41
    • 0035884510 scopus 로고    scopus 로고
    • A truncated precursor form of prostate-specific antigen is a more specific serum marker of prostate cancer
    • Mikolajczyk SD, et al. A truncated precursor form of prostate-specific antigen is a more specific serum marker of prostate cancer. Cancer Res. 2001;61(18): 6958-63.
    • (2001) Cancer Res , vol.61 , Issue.18 , pp. 6958-6963
    • Mikolajczyk, S.D.1
  • 42
    • 0037319253 scopus 로고    scopus 로고
    • Proenzyme psa for the early detection of prostate cancer in the 2.5-4.0 ng/ml total psa range: preliminary analysis
    • Sokoll LJ, et al. Proenzyme psa for the early detection of prostate cancer in the 2.5-4.0 ng/ml total psa range: preliminary analysis. Urology. 2003;61(2): 274-6.
    • (2003) Urology , vol.61 , Issue.2 , pp. 274-276
    • Sokoll, L.J.1
  • 43
    • 2442600143 scopus 로고    scopus 로고
    • Serum pro-prostate specific antigen preferentially detects aggressive prostate cancers in men with 2 to 4 ng/ml prostate specific antigen
    • Catalona WJ, et al. Serum pro-prostate specific antigen preferentially detects aggressive prostate cancers in men with 2 to 4 ng/ml prostate specific antigen. J Urol. 2004;171(6 Pt 1):2239-44.
    • (2004) J Urol , vol.171 , Issue.6 , pp. 2239-2244
    • Catalona, W.J.1
  • 44
    • 0242692670 scopus 로고    scopus 로고
    • Serum pro prostate specific antigen improves cancer detection compared to free and complexed prostate specific antigen in men with prostate specific antigen 2 to 4 ng/ml
    • Catalona WJ, et al. Serum pro prostate specific antigen improves cancer detection compared to free and complexed prostate specific antigen in men with prostate specific antigen 2 to 4 ng/ml. J Urol. 2003;170(6 Pt 1):2181-5.
    • (2003) J Urol , vol.170 , Issue.6 , pp. 2181-2185
    • Catalona, W.J.1
  • 45
    • 58849091840 scopus 로고    scopus 로고
    • A [-2]proPSA-based artificial neural network significantly improves differentiation between prostate cancer and benign prostatic diseases
    • Stephan C, et al. A [-2]proPSA-based artificial neural network significantly improves differentiation between prostate cancer and benign prostatic diseases. Prostate. 2009;69(2):198-207.
    • (2009) Prostate , vol.69 , Issue.2 , pp. 198-207
    • Stephan, C.1
  • 46
    • 73149087871 scopus 로고    scopus 로고
    • Pro-prostate-specific antigen measurements in serum and tissue are associated with treatment necessity among men enrolled in expectant management for prostate cancer
    • Makarov DV, et al. Pro-prostate-specific antigen measurements in serum and tissue are associated with treatment necessity among men enrolled in expectant management for prostate cancer. Clin Cancer Res. 2009;15(23):7316-21.
    • (2009) Clin Cancer Res , vol.15 , Issue.23 , pp. 7316-7321
    • Makarov, D.V.1
  • 47
    • 77952082471 scopus 로고    scopus 로고
    • A prospective, multicenter, National Cancer Institute early detection research network study of [-2]proPSA: improving prostate cancer detection and correlating with cancer aggressiveness
    • Sokoll LJ, et al. A prospective, multicenter, National Cancer Institute early detection research network study of [-2]proPSA: improving prostate cancer detection and correlating with cancer aggressiveness. Cancer Epidemiol Biomarkers Prev. 2010;19(5): 1193-200.
    • (2010) Cancer Epidemiol Biomarkers Prev , vol.19 , Issue.5 , pp. 1193-1200
    • Sokoll, L.J.1
  • 48
    • 77953717799 scopus 로고    scopus 로고
    • Pre-analytical in-vitro stability of [-2]proPSA in blood and serum
    • Semjonow A, et al. Pre-analytical in-vitro stability of [-2]proPSA in blood and serum. Clin Biochem. 2010;43(10-11):926-8.
    • (2010) Clin Biochem , vol.43 , Issue.10-11 , pp. 926-928
    • Semjonow, A.1
  • 49
    • 0033963210 scopus 로고    scopus 로고
    • "BPSA," a specific molecular form of free prostate-specific antigen, is found predominantly in the transition zone of patients with nodular benign prostatic hyperplasia
    • Mikolajczyk SD, et al. "BPSA," a specific molecular form of free prostate-specific antigen, is found predominantly in the transition zone of patients with nodular benign prostatic hyperplasia. Urology. 2000;55(1):41-5.
    • (2000) Urology , vol.55 , Issue.1 , pp. 41-45
    • Mikolajczyk, S.D.1
  • 50
    • 2342460342 scopus 로고    scopus 로고
    • Serum BPSA outperforms both total PSA and free PSA as a predictor of prostatic enlargement in men without prostate cancer
    • discussion 910-1
    • Canto EI, et al. Serum BPSA outperforms both total PSA and free PSA as a predictor of prostatic enlargement in men without prostate cancer. Urology. 2004;63(5):905-10. discussion 910-1.
    • (2004) Urology , vol.63 , Issue.5 , pp. 905-910
    • Canto, E.I.1
  • 51
    • 70349459448 scopus 로고    scopus 로고
    • Benign prostatic hyperplasia-associated free prostate-specific antigen improves detection of prostate cancer in an artificial neural network
    • Stephan C, et al. Benign prostatic hyperplasia-associated free prostate-specific antigen improves detection of prostate cancer in an artificial neural network. Urology. 2009;74(4):873-7.
    • (2009) Urology , vol.74 , Issue.4 , pp. 873-877
    • Stephan, C.1
  • 52
    • 0034921328 scopus 로고    scopus 로고
    • Discrimination of prostate cancer from benign disease by plasma measurement of intact, free prostate-specific antigen lacking an internal cleavage site at Lys145-Lys146
    • Nurmikko P, et al. Discrimination of prostate cancer from benign disease by plasma measurement of intact, free prostate-specific antigen lacking an internal cleavage site at Lys145-Lys146. Clin Chem. 2001;47(8):1415-23.
    • (2001) Clin Chem , vol.47 , Issue.8 , pp. 1415-1423
    • Nurmikko, P.1
  • 53
    • 20144362578 scopus 로고    scopus 로고
    • Association of free-prostate specific antigen subfractions and human glandular kallikrein 2 with volume of benign and malignant prostatic tissue
    • Steuber T, et al. Association of free-prostate specific antigen subfractions and human glandular kallikrein 2 with volume of benign and malignant prostatic tissue. Prostate. 2005;63(1):13-8.
    • (2005) Prostate , vol.63 , Issue.1 , pp. 13-18
    • Steuber, T.1
  • 54
    • 0035018273 scopus 로고    scopus 로고
    • The new human tissue kallikrein gene family: structure, function, and association to disease
    • Yousef GM, Diamandis EP. The new human tissue kallikrein gene family: structure, function, and association to disease. Endocr Rev. 2001;22(2): 184-204.
    • (2001) Endocr Rev , vol.22 , Issue.2 , pp. 184-204
    • Yousef, G.M.1    Diamandis, E.P.2
  • 55
    • 0033993446 scopus 로고    scopus 로고
    • Serum human glandular kallikrein-2 protease levels predict the presence of prostate cancer among men with elevated prostate-specific antigen
    • Nam RK, et al. Serum human glandular kallikrein-2 protease levels predict the presence of prostate cancer among men with elevated prostate-specific antigen. J Clin Oncol. 2000;18(5):1036-42.
    • (2000) J Clin Oncol , vol.18 , Issue.5 , pp. 1036-1042
    • Nam, R.K.1
  • 56
    • 0034185675 scopus 로고    scopus 로고
    • Clinical value of human glandular kallikrein 2 and free and total prostate-specific antigen in serum from a population of men with prostatespecific antigen levels 3.0 ng/mL or greater
    • Becker C, et al. Clinical value of human glandular kallikrein 2 and free and total prostate-specific antigen in serum from a population of men with prostatespecific antigen levels 3.0 ng/mL or greater. Urology. 2000;55(5):694-9.
    • (2000) Urology , vol.55 , Issue.5 , pp. 694-699
    • Becker, C.1
  • 57
    • 0033992278 scopus 로고    scopus 로고
    • Discrimination of men with prostate cancer from those with benign disease by measurements of human glandular kallikrein 2 (HK2) in serum
    • Becker C, et al. Discrimination of men with prostate cancer from those with benign disease by measurements of human glandular kallikrein 2 (HK2) in serum. J Urol. 2000;163(1):311-6.
    • (2000) J Urol , vol.163 , Issue.1 , pp. 311-316
    • Becker, C.1
  • 58
    • 0034791830 scopus 로고    scopus 로고
    • Human glandular kallikrein 2 levels in serum for discrimination of pathologically organconfined from locally-advanced prostate cancer in total PSA-levels below 10 ng/ml
    • Haese A, et al. Human glandular kallikrein 2 levels in serum for discrimination of pathologically organconfined from locally-advanced prostate cancer in total PSA-levels below 10 ng/ml. Prostate. 2001;49(2): 101-9.
    • (2001) Prostate , vol.49 , Issue.2 , pp. 101-109
    • Haese, A.1
  • 59
    • 17744400811 scopus 로고    scopus 로고
    • In prostatism patients the ratio of human glandular kallikrein to free PSA improves the discrimination between prostate cancer and benign hyperplasia within the diagnostic "gray zone" of total PSA 4 to 10 ng/mL
    • Kwiatkowski MK, et al. In prostatism patients the ratio of human glandular kallikrein to free PSA improves the discrimination between prostate cancer and benign hyperplasia within the diagnostic "gray zone" of total PSA 4 to 10 ng/mL. Urology. 1998;52(3):360-5.
    • (1998) Urology , vol.52 , Issue.3 , pp. 360-365
    • Kwiatkowski, M.K.1
  • 60
    • 0032535786 scopus 로고    scopus 로고
    • The importance of human glandular kallikrein and its correlation with different prostate specific antigen serum forms in the detection of prostate carcinoma
    • Recker F, et al. The importance of human glandular kallikrein and its correlation with different prostate specific antigen serum forms in the detection of prostate carcinoma. Cancer. 1998;83(12):2540-7.
    • (1998) Cancer , vol.83 , Issue.12 , pp. 2540-2547
    • Recker, F.1
  • 61
    • 4444269507 scopus 로고    scopus 로고
    • Prognostic value of combined "triple"-reverse transcription-PCR analysis for prostate-specific antigen, human kallikrein 2, and prostate-specific membrane antigen mRNA in peripheral blood and lymph nodes of prostate cancer patients
    • Kurek R, et al. Prognostic value of combined "triple"-reverse transcription-PCR analysis for prostate-specific antigen, human kallikrein 2, and prostate-specific membrane antigen mRNA in peripheral blood and lymph nodes of prostate cancer patients. Clin Cancer Res. 2004;10(17):5808-14.
    • (2004) Clin Cancer Res , vol.10 , Issue.17 , pp. 5808-5814
    • Kurek, R.1
  • 62
    • 0036547696 scopus 로고    scopus 로고
    • Urokinase-type plasminogen activator: a potent marker of metastatic potential in human cancers
    • Duffy MJ. Urokinase-type plasminogen activator: a potent marker of metastatic potential in human cancers. Biochem Soc Trans. 2002;30(2):207-10.
    • (2002) Biochem Soc Trans , vol.30 , Issue.2 , pp. 207-210
    • Duffy, M.J.1
  • 63
    • 62649132399 scopus 로고    scopus 로고
    • Predictive value of the differential expression of the urokinase plasminogen activation axis in radical prostatectomy patients
    • Gupta A, et al. Predictive value of the differential expression of the urokinase plasminogen activation axis in radical prostatectomy patients. Eur Urol. 2009;55(5):1124-33.
    • (2009) Eur Urol , vol.55 , Issue.5 , pp. 1124-1133
    • Gupta, A.1
  • 64
    • 33847617415 scopus 로고    scopus 로고
    • Free PSA isoforms and intact and cleaved forms of urokinase plasminogen activator receptor in serum improve selection of patients for prostate cancer biopsy
    • Steuber T, et al. Free PSA isoforms and intact and cleaved forms of urokinase plasminogen activator receptor in serum improve selection of patients for prostate cancer biopsy. Int J Cancer. 2007;120(7): 1499-504.
    • (2007) Int J Cancer , vol.120 , Issue.7 , pp. 1499-1504
    • Steuber, T.1
  • 65
    • 20244364627 scopus 로고
    • Urokinase-type plasminogen activator as a marker for the formation of distant metastases in prostatic carcinomas
    • Hienert G, et al. Urokinase-type plasminogen activator as a marker for the formation of distant metastases in prostatic carcinomas. J Urol. 1988;140(6): 1466-9.
    • (1988) J Urol , vol.140 , Issue.6 , pp. 1466-1469
    • Hienert, G.1
  • 66
    • 0033119221 scopus 로고    scopus 로고
    • Elevation of serum levels of urokinase- type plasminogen activator and its receptor is associated with disease progression and prognosis in patients with prostate cancer
    • Miyake H, et al. Elevation of serum levels of urokinase- type plasminogen activator and its receptor is associated with disease progression and prognosis in patients with prostate cancer. Prostate. 1999;39(2): 123-9.
    • (1999) Prostate , vol.39 , Issue.2 , pp. 123-129
    • Miyake, H.1
  • 67
    • 33846978442 scopus 로고    scopus 로고
    • Association of the circulating levels of the urokinase system of plasminogen activation with the presence of prostate cancer and invasion, progression, and metastasis
    • Shariat SF, et al. Association of the circulating levels of the urokinase system of plasminogen activation with the presence of prostate cancer and invasion, progression, and metastasis. J Clin Oncol. 2007;25(4):349-55.
    • (2007) J Clin Oncol , vol.25 , Issue.4 , pp. 349-355
    • Shariat, S.F.1
  • 68
    • 0035367931 scopus 로고    scopus 로고
    • Preoperative plasma levels of transforming growth factor beta(1) (TGF-beta(1)) strongly predict progression in patients undergoing radical prostatectomy
    • Shariat SF, et al. Preoperative plasma levels of transforming growth factor beta(1) (TGF-beta(1)) strongly predict progression in patients undergoing radical prostatectomy. J Clin Oncol. 2001;19(11): 2856-64.
    • (2001) J Clin Oncol , vol.19 , Issue.11 , pp. 2856-2864
    • Shariat, S.F.1
  • 69
    • 0027511966 scopus 로고
    • Association of transforming growth factor-beta 1 with prostate cancer: an immunohistochemical study
    • Truong LD, et al. Association of transforming growth factor-beta 1 with prostate cancer: an immunohistochemical study. Hum Pathol. 1993;24(1):4-9.
    • (1993) Hum Pathol , vol.24 , Issue.1 , pp. 4-9
    • Truong, L.D.1
  • 70
    • 1642392553 scopus 로고    scopus 로고
    • Association of pre- and postoperative plasma levels of transforming growth factor beta(1) and interleukin 6 and its soluble receptor with prostate cancer progression
    • Shariat SF, et al. Association of pre- and postoperative plasma levels of transforming growth factor beta(1) and interleukin 6 and its soluble receptor with prostate cancer progression. Clin Cancer Res. 2004;10(6): 1992-9.
    • (2004) Clin Cancer Res , vol.10 , Issue.6 , pp. 1992-1999
    • Shariat, S.F.1
  • 71
    • 2942583124 scopus 로고    scopus 로고
    • Tissue expression of transforming growth factor-beta1 and its receptors: correlation with pathologic features and biochemical progression in patients undergoing radical prostatectomy
    • Shariat SF, et al. Tissue expression of transforming growth factor-beta1 and its receptors: correlation with pathologic features and biochemical progression in patients undergoing radical prostatectomy. Urology. 2004;63(6):1191-7.
    • (2004) Urology , vol.63 , Issue.6 , pp. 1191-1197
    • Shariat, S.F.1
  • 72
    • 0035892767 scopus 로고    scopus 로고
    • Preoperative plasma levels of transforming growth factor beta(1) strongly predict clinical outcome in patients with bladder carcinoma
    • Shariat SF, et al. Preoperative plasma levels of transforming growth factor beta(1) strongly predict clinical outcome in patients with bladder carcinoma. Cancer. 2001;92(12):2985-92.
    • (2001) Cancer , vol.92 , Issue.12 , pp. 2985-2992
    • Shariat, S.F.1
  • 73
    • 0028902318 scopus 로고
    • Elevated plasma levels of TGFbeta 1 in patients with invasive prostate cancer
    • Ivanovic V, et al. Elevated plasma levels of TGFbeta 1 in patients with invasive prostate cancer. Nat Med. 1995;1(4):282-4.
    • (1995) Nat Med , vol.1 , Issue.4 , pp. 282-284
    • Ivanovic, V.1
  • 74
    • 0032532688 scopus 로고    scopus 로고
    • Interleukin-6 regulates prostatespecific protein expression in prostate carcinoma cells by activation of the androgen receptor
    • Hobisch A, et al. Interleukin-6 regulates prostatespecific protein expression in prostate carcinoma cells by activation of the androgen receptor. Cancer Res. 1998;58(20):4640-5.
    • (1998) Cancer Res , vol.58 , Issue.20 , pp. 4640-4645
    • Hobisch, A.1
  • 75
    • 0035180451 scopus 로고    scopus 로고
    • Interleukin-6 is an autocrine growth factor in human prostate cancer
    • Giri D, Ozen M, Ittmann M. Interleukin-6 is an autocrine growth factor in human prostate cancer. Am J Pathol. 2001;159(6):2159-65.
    • (2001) Am J Pathol , vol.159 , Issue.6 , pp. 2159-2165
    • Giri, D.1    Ozen, M.2    Ittmann, M.3
  • 76
    • 3042823539 scopus 로고    scopus 로고
    • Serum levels of IL-6 and TNFalpha correlate with clinicopathological features and patient survival in patients with prostate cancer
    • Michalaki V, et al. Serum levels of IL-6 and TNFalpha correlate with clinicopathological features and patient survival in patients with prostate cancer. Br J Cancer. 2004;90(12):2312-6.
    • (2004) Br J Cancer , vol.90 , Issue.12 , pp. 2312-2316
    • Michalaki, V.1
  • 77
    • 0033911711 scopus 로고    scopus 로고
    • Serum interleukin 6 as a prognostic factor in patients with prostate cancer
    • Nakashima J, et al. Serum interleukin 6 as a prognostic factor in patients with prostate cancer. Clin Cancer Res. 2000;6(7):2702-6.
    • (2000) Clin Cancer Res , vol.6 , Issue.7 , pp. 2702-2706
    • Nakashima, J.1
  • 78
    • 64249115346 scopus 로고    scopus 로고
    • Circulating prediagnostic interleukin-6 and C-reactive protein and prostate cancer incidence and mortality
    • Stark JR, et al. Circulating prediagnostic interleukin-6 and C-reactive protein and prostate cancer incidence and mortality. Int J Cancer. 2009;124(11):2683-9.
    • (2009) Int J Cancer , vol.124 , Issue.11 , pp. 2683-2689
    • Stark, J.R.1
  • 79
    • 0026646785 scopus 로고
    • Endoglin is a component of the transforming growth factor-beta receptor system in human endothelial cells
    • Cheifetz S, et al. Endoglin is a component of the transforming growth factor-beta receptor system in human endothelial cells. J Biol Chem. 1992;267(27): 19027-30.
    • (1992) J Biol Chem , vol.267 , Issue.27 , pp. 19027-19030
    • Cheifetz, S.1
  • 80
    • 0036591699 scopus 로고    scopus 로고
    • Endoglin (CD105) is expressed on immature blood vessels and is a marker for survival in prostate cancer
    • Wikstrom P, et al. Endoglin (CD105) is expressed on immature blood vessels and is a marker for survival in prostate cancer. Prostate. 2002;51(4):268-75.
    • (2002) Prostate , vol.51 , Issue.4 , pp. 268-275
    • Wikstrom, P.1
  • 81
    • 58149290234 scopus 로고    scopus 로고
    • Endoglin (CD105) as a urinary and serum marker of prostate cancer
    • Fujita K, et al. Endoglin (CD105) as a urinary and serum marker of prostate cancer. Int J Cancer. 2009;124(3):664-9.
    • (2009) Int J Cancer , vol.124 , Issue.3 , pp. 664-669
    • Fujita, K.1
  • 82
    • 40949088879 scopus 로고    scopus 로고
    • Use of preoperative plasma endoglin for prediction of lymph node metastasis in patients with clinically localized prostate cancer
    • Karam JA, et al. Use of preoperative plasma endoglin for prediction of lymph node metastasis in patients with clinically localized prostate cancer. Clin Cancer Res. 2008;14(5):1418-22.
    • (2008) Clin Cancer Res , vol.14 , Issue.5 , pp. 1418-1422
    • Karam, J.A.1
  • 83
    • 50349099343 scopus 로고    scopus 로고
    • Preoperative plasma endoglin levels predict biochemical progression after radical prostatectomy
    • Svatek RS, et al. Preoperative plasma endoglin levels predict biochemical progression after radical prostatectomy. Clin Cancer Res. 2008;14(11):3362-6.
    • (2008) Clin Cancer Res , vol.14 , Issue.11 , pp. 3362-3366
    • Svatek, R.S.1
  • 84
    • 0037012476 scopus 로고    scopus 로고
    • Alpha-Methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer
    • Rubin MA, et al. Alpha-Methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer. JAMA. 2002;287(13):1662-70.
    • (2002) JAMA , vol.287 , Issue.13 , pp. 1662-1670
    • Rubin, M.A.1
  • 85
    • 4644372687 scopus 로고    scopus 로고
    • Alpha-methylacyl-CoA racemase: a multi-institutional study of a new prostate cancer marker
    • Jiang Z, et al. Alpha-methylacyl-CoA racemase: a multi-institutional study of a new prostate cancer marker. Histopathology. 2004;45(3):218-25.
    • (2004) Histopathology , vol.45 , Issue.3 , pp. 218-225
    • Jiang, Z.1
  • 86
    • 2942612648 scopus 로고    scopus 로고
    • Humoral immune response to alpha-methylacyl-CoA racemase and prostate cancer
    • Sreekumar A, et al. Humoral immune response to alpha-methylacyl-CoA racemase and prostate cancer. J Natl Cancer Inst. 2004;96(11):834-43.
    • (2004) J Natl Cancer Inst , vol.96 , Issue.11 , pp. 834-843
    • Sreekumar, A.1
  • 87
    • 26844486558 scopus 로고    scopus 로고
    • Can p503s, p504s and p510s gene expression in peripheral-blood be useful as a marker of prostatic cancer
    • Cardillo MR, et al. Can p503s, p504s and p510s gene expression in peripheral-blood be useful as a marker of prostatic cancer? BMC Cancer. 2005; 5:111.
    • (2005) BMC Cancer , vol.5 , pp. 111
    • Cardillo, M.R.1
  • 88
    • 20144366038 scopus 로고    scopus 로고
    • Serum antibodies to huntingtin interacting protein-1: a new blood test for prostate cancer
    • Bradley SV, et al. Serum antibodies to huntingtin interacting protein-1: a new blood test for prostate cancer. Cancer Res. 2005;65(10):4126-33.
    • (2005) Cancer Res , vol.65 , Issue.10 , pp. 4126-4133
    • Bradley, S.V.1
  • 89
    • 25144483466 scopus 로고    scopus 로고
    • Autoantibody signatures in prostate cancer
    • Wang X, et al. Autoantibody signatures in prostate cancer. N Engl J Med. 2005;353(12):1224-35.
    • (2005) N Engl J Med , vol.353 , Issue.12 , pp. 1224-1235
    • Wang, X.1
  • 90
    • 78049465549 scopus 로고    scopus 로고
    • Use of a combination of biomarkers in serum and urine to improve detection of prostate cancer
    • Prior C, et al. Use of a combination of biomarkers in serum and urine to improve detection of prostate cancer. World J Urol. 2010;28(6):681-6.
    • (2010) World J Urol , vol.28 , Issue.6 , pp. 681-686
    • Prior, C.1
  • 91
    • 79953700273 scopus 로고    scopus 로고
    • A multiplex model of combining genebased, protein-based, and metabolite-based with positive and negative markers in urine for the early diagnosis of prostate cancer
    • Cao DL, et al. A multiplex model of combining genebased, protein-based, and metabolite-based with positive and negative markers in urine for the early diagnosis of prostate cancer. Prostate. 2011;71(7): 700-10.
    • (2011) Prostate , vol.71 , Issue.7 , pp. 700-710
    • Cao, D.L.1
  • 92
    • 65549127138 scopus 로고    scopus 로고
    • Pre-treatment biomarker levels improve the accuracy of post-prostatectomy nomogram for prediction of biochemical recurrence
    • Svatek RS, et al. Pre-treatment biomarker levels improve the accuracy of post-prostatectomy nomogram for prediction of biochemical recurrence. Prostate. 2009;69(8):886-94.
    • (2009) Prostate , vol.69 , Issue.8 , pp. 886-894
    • Svatek, R.S.1
  • 93
    • 77953688557 scopus 로고    scopus 로고
    • Reducing unnecessary biopsy during prostate cancer screening using a four-kallikrein panel: an independent replication
    • Vickers A, et al. Reducing unnecessary biopsy during prostate cancer screening using a four-kallikrein panel: an independent replication. J Clin Oncol. 2010;28(15):2493-8.
    • (2010) J Clin Oncol , vol.28 , Issue.15 , pp. 2493-2498
    • Vickers, A.1
  • 94
    • 78549255938 scopus 로고    scopus 로고
    • A panel of kallikrein markers can predict outcome of prostate biopsy following clinical work-up: an independent validation study from the European Randomized Study of prostate cancer screening, France
    • Benchikh A, et al. A panel of kallikrein markers can predict outcome of prostate biopsy following clinical work-up: an independent validation study from the European Randomized Study of prostate cancer screening, France. BMC Cancer. 2010;10:635.
    • (2010) BMC Cancer , vol.10 , pp. 635
    • Benchikh, A.1
  • 95
    • 77952800766 scopus 로고    scopus 로고
    • Impact of recent screening on predicting the outcome of prostate cancer biopsy in men with elevated prostate-specific antigen: data from the European Randomized Study of prostate cancer screening in Gothenburg, Sweden
    • Vickers AJ, et al. Impact of recent screening on predicting the outcome of prostate cancer biopsy in men with elevated prostate-specific antigen: data from the European Randomized Study of prostate cancer screening in Gothenburg, Sweden. Cancer. 2010; 116(11):2612-20.
    • (2010) Cancer , vol.116 , Issue.11 , pp. 2612-2620
    • Vickers, A.J.1
  • 96
    • 77953715079 scopus 로고    scopus 로고
    • A four-kallikrein panel predicts prostate cancer in men with recent screening: data from the European Randomized Study of screening for prostate cancer, Rotterdam
    • Vickers AJ, et al. A four-kallikrein panel predicts prostate cancer in men with recent screening: data from the European Randomized Study of screening for prostate cancer, Rotterdam. Clin Cancer Res. 2010;16(12):3232-9.
    • (2010) Clin Cancer Res , vol.16 , Issue.12 , pp. 3232-3239
    • Vickers, A.J.1
  • 97
    • 77955981143 scopus 로고    scopus 로고
    • A four-kallikrein panel for the prediction of repeat prostate biopsy: data from the European Randomized Study of prostate cancer screening in Rotterdam, Netherlands
    • Gupta A, et al. A four-kallikrein panel for the prediction of repeat prostate biopsy: data from the European Randomized Study of prostate cancer screening in Rotterdam, Netherlands. Br J Cancer. 2010;103(5): 708-14.
    • (2010) Br J Cancer , vol.103 , Issue.5 , pp. 708-714
    • Gupta, A.1
  • 98
    • 0035667565 scopus 로고    scopus 로고
    • Plasma levels of interleukin-6 and its soluble receptor are associated with prostate cancer progression and metastasis
    • Shariat SF, et al. Plasma levels of interleukin-6 and its soluble receptor are associated with prostate cancer progression and metastasis. Urology. 2001;58(6): 1008-15.
    • (2001) Urology , vol.58 , Issue.6 , pp. 1008-1015
    • Shariat, S.F.1
  • 99
    • 2442641793 scopus 로고    scopus 로고
    • Association of preoperative plasma levels of vascular endothelial growth factor and soluble vascular cell adhesion molecule-1 with lymph node status and biochemical progression after radical prostatectomy
    • Shariat SF, et al. Association of preoperative plasma levels of vascular endothelial growth factor and soluble vascular cell adhesion molecule-1 with lymph node status and biochemical progression after radical prostatectomy. J Clin Oncol. 2004;22(9):1655-63.
    • (2004) J Clin Oncol , vol.22 , Issue.9 , pp. 1655-1663
    • Shariat, S.F.1
  • 100
    • 41149119907 scopus 로고    scopus 로고
    • External validation of a biomarkerbased preoperative nomogram predicts biochemical recurrence after radical prostatectomy
    • Shariat SF, et al. External validation of a biomarkerbased preoperative nomogram predicts biochemical recurrence after radical prostatectomy. J Clin Oncol. 2008;26(9):1526-31.
    • (2008) J Clin Oncol , vol.26 , Issue.9 , pp. 1526-1531
    • Shariat, S.F.1
  • 101
    • 0038175364 scopus 로고    scopus 로고
    • Detection of clinically significant, occult prostate cancer metastases in lymph nodes using a splice variant-specific rt-PCR assay for human glandular kallikrein
    • Shariat SF, et al. Detection of clinically significant, occult prostate cancer metastases in lymph nodes using a splice variant-specific rt-PCR assay for human glandular kallikrein. J Clin Oncol. 2003; 21(7):1223-31.
    • (2003) J Clin Oncol , vol.21 , Issue.7 , pp. 1223-1231
    • Shariat, S.F.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.